Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 20/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10057874 | 0.96 | MLNR (0.80) | MLNR | |
| SCHEMBL73783 | 0.95 | MLNR (0.84) | MLNR | |
| SCHEMBL75379 | 0.92 | MLNR (0.88) | MLNR | |
| SCHEMBL73797 | 0.91 | MLNR (0.85) | MLNR | |
| SCHEMBL12220294 | 0.91 | MLNR (0.87) | MLNR | |
| SCHEMBL12219741 | 0.91 | MLNR (0.89) | MLNR | |
| SCHEMBL10051182 | 0.91 | MLNR (0.70) | MLNR | |
| SCHEMBL74135 | 0.90 | MLNR (1.00) | MLNR | |
| SCHEMBL13392515 | 0.90 | MLNR (0.83) | MLNR | |
| SCHEMBL73745 | 0.90 | MLNR (0.82) | MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-06-28 | — | — | US | disclosed |
| US-7521420-B2 | Macrocyclic antagonists of the motilin receptor | TRANZYME PHARMA, INC. (CA) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | MLNR 1/4885 |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | MLNR 1/4885 |
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CCKAR | MLNR 1/4885 |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | MLNR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.